The National Institutes on Drug Abuse states “CBD is a cannabinoid that doesn’t make people “high.” It may be useful in reducing pain and inflammation, controlling epileptic seizures, and possibly even treating mental illness and addictions.”

• National Institutes on Drug Abuse, Drug Facts, Marijuana as Medicine, Revised April 2017: https://www.drugabuse.gov/publications/drugfacts/marijuana-medicine

“Cannabidiol (CBD) can help treat seizures, can reduce anxiety and paranoia, and can counteract the “high” caused by THC.”

• American Cancer Society: https://www.cancer.org/treatment/treatments-and-side-effects/complementary-and-alternative-medicine/marijuana-and-cancer.html

WADA, created by the International Olympic Committee to coordinate and monitor drug use in sports removed CBD from the 2018 Banned substances list. “Cannabidiol is no longer prohibited.”

• World Anti-Doping Agency (WADA)  https://www.wada-ama.org/sites/default/files/prohibited_list_2018_summary_of_modifications_en.pdf

The discovery of the Endocannabinoid System (ECS)

“Though still unknown to most researchers and medical professionals because of the worldwide prohibition of marijuana, the importance of the endocannabinoid system is growing daily. It has been called the “supercomputer that regulates homeostasis in the human body.” Because receptors are found throughout the brain and in every major organ, this system is thought to be involved in most disease state. This is one reason that Cannabis treats so many varied illnesses. Mechoulam has been investigating this compound longer and more thoughtfully than any other scientist. He has unearthed Cannabis’s role in treating seizure disorders, schizophrenia and PTSD, plus its impact on other functions that govern human health, such as the rapidity with which an infant bonds with his mother. He has been awarded TK scientific prizes and is universally acknowledged as the “father of cannabinoid medicine.”

• The Scientist —The Life And Work Of Raphael Mechoulam, Zach Klein, Fundación CANNA  http://mechoulamthescientist.com/

“CBD is generally well tolerated with a good safety profile. Reported adverse effects may be as a result of drug-drug interactions between CBD and patients’ existing medications.  Several countries have modified their national controls to accommodate CBD as a medicinal product.  To date, there is no evidence of recreational use of CBD or any public health related problems associated with the use of pure CBD.”

• World Health Organization, Cannabidiol (CBD) Pre-Review Report Agenda Item 5.2,  Expert Committee on Drug Dependence, Thirty-ninth Meeting Geneva, 6-10 November 2017, http://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdf

“Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention”

• Patent number 6630507,  “Cannabinoids as antioxidants and neuroprotectants”, The United States Of America As Represented By The Department Of Health And Human Services.  https://patents.google.com/patent/US6630507

“Cannabidiol is a phytocannabinoid derived from Cannabis species, which is devoid of psychoactive activity, with analgesic, anti-inflammatory, antineoplastic and chemopreventive activities. Upon administration, cannabidiol (CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity through various mechanisms, which likely do not involve signaling by cannabinoid receptor 1 (CB1), CB2, or vanilloid receptor.”

• National Institutes of Health, U.S. Library of Medicine, National Center for Biotechnology Information, PubChem, Compound Summary for CID 644019, Cannabidiol https://pubchem.ncbi.nlm.nih.gov/compound/cannabidiol#section=Top

“Cannabis and cannabinoids represent an alternative to analgesics of all kinds, anti-anxiety, anti-depressants, anti-panic, anti-obsessive-compulsive; gastrointestinal agents including anti-spasmodics and antiinflammatory medications; migraine preparations; anticonvulsants; appetite stimulants; immuno-modulators; muscle relaxants; multiple sclerosis management medications; glaucoma treatments; sedative and hypnotic agents; Tourette’s syndrome agents, and anti-cancer agents.”

• Society of Cannabis Clinicians, On Issuing Cannabis Recommendations, Stacey Kerr, MD,  O’Shaughnessy’s, Summer 2010,  http://cannabisclinicians.org/wp-content/uploads/2011/08/Kerr-2010-Making-Recs.pdf

“Cannabidiol Medicine May Help Patients With Epilepsy Who Don’t Benefit From Standard Medication, Research Suggests.”

• American Epilepsy Society https://www.aesnet.org/about_aes/press_releases/cannabidiol122016